Jul 2026· Research Square· 1 citation· 89 references
Medicine
TL;DR
The immortalized non-tumorigenic breast epithelial cell line (MCF10A) develops neoplastic clones under fluctuating conditions in-vitro that mimic the harsh tumor microenvironment and is identified as a potential therapeutic target against epithelial-mesenchymal plasticity and metastatic spread in breast cancer.
Abstract
How environmental selective pressures contribute to the emergence of a neoplastic tumorigenic state, remains incompletely understood. Here we show that the immortalized non-tumorigenic breast epithelial cell line (MCF10A) develops neoplastic clones under fluctuating conditions in-vitro that mimic the harsh tumor microenvironment. Long-term evolutionary experiments and genomic landscape analyses of the clones identified ROS as the dominant clonal mutational signature that facilitates the acquisition of oncogenic driver mutations and the onset of the Warburg phenotype. Single cell multi-omics and brightfield microscopy further elucidate that each clone adopts two plastic phenotypic states, epithelial-like and mesenchymal-like, the transition between which is epigenetically mediated by de novo expression of Grainyhead-like Transcription Factor 2 (GRHL2), following environmental cues from soluble factors and cell adhesion. Additional in-vitro experiments indicate the role of this plasticity in metastasis. Analysis of 70 human breast cancer cell lines and 2 independent breast cancer patient cohorts confirmed the generality of this mechanism and its epigenetic regulation in patients. Thus, this study elucidates fundamental evolutionary mechanisms behind tumorigenesis and identifies GRHL2 as a potential therapeutic target against epithelial-mesenchymal plasticity and metastatic spread in breast cancer.
Tumor plasticity and microenvironmental heterogeneity are established as an integrated, evolving system that fuels metastasis and limits durable treatment responses.
G. Dagar, M. Dagar, Ashna Gupta et al.· MedComm· 0 citations
These findings support a model in which normal-like cells tolerate oncogenic mutations not because most cells fail to respond, but because a p53-independent, cell-intrinsic barrier limits the stabilization of malignant transformation following a transient period of heightened plasticity.
Costakis Frangou, A. Safina, M. Commane et al.· bioRxiv· 0 citations
Breast cancer is a heterogeneous disease in which a single oncogenic driver can give rise to divergent tumor phenotypes. How oncogenic mutations generate epithelial state plasticity and coordinately remodel the surrounding tissue remains incompletely understood. Here, we applied longitudinal single cell RNA-sequencing...
Jennifer T. Le, Eun K. Kim, Vasudha Srivastava et al.· bioRxiv· 0 citations
This review evaluating how the antagonistic interplay between Polycomb and Trithorax complexes, chromatin modifier activity, and enhancer reprogramming affects lineage identity and enables multi-lineage plasticity in cancer underscores epigenetic deregulation as a primary driver of lineage plasticity and intratumoral h...
Ezgi Boyvatlı, Burcu Akman, E. Bağırsakçı et al.· FEBS Letters· 0 citations
A mathematical model of tumor growth under fluctuating conditions with stochastic phenotypic epithelial-mesenchymal switch as the main mechanism of adaptation is developed, and non-trivial evolutionary outcomes are revealed, depending on the relative time scales of the underlying processes.
Sanasar G. Babajanyan, Y. Wolf, R. Canevarolo et al.· bioRxiv· 0 citations
These findings suggest a highly conserved role for HDAC9 and class IIA HDACs in vertebrate pancreatic tumorigenesis and may lead to new strategies for reactivating (normal acinar/epithelial) differentiation programs to intercept and treat PDAC.
Somer Matar, Sandra Blázquez-Araguás, Andrea Diéguez-Docampo et al.· Cellular and Molecular Gastr...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.